Navigation Links
ImpediMed and Metagenics Announce Agreement
Date:10/2/2008

BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. 2 /PRNewswire/ -- ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics' Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.

"We've seen the synergies of combining ImpediMed's products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals," said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. "Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision."

ImpediMed CEO Greg Brown said, "Metagenics has been an outstanding Australian partner using ImpediMed's body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles."

About Metagenics, Inc.

Metagenics, Inc. is a life sciences company and leading developer and manufacturer of science-based nutraceuticals medical foods, and therapeutic lifestyle change programs marketed to healthcare practitioners worldwide. It is headquartered in San Clemente, Calif. with manufacturing and multiple research facilities located in Gig Harbor, Wash., including its MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information about Metagenics, please visit http://www.metagenics.com.

About ImpediMed Limited

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of fluid status and body composition. ImpediMed's product range includes medical devices for body composition analysis and early detection and monitoring of secondary lymphedema in cancer survivors. ImpediMed's products are TGA and FDA cleared as well as CE marked for global distribution. For more information about ImpediMed, please visit http://www.impedimed.com

Contact:

Joseline Davison

Metagenics, Inc.

949-369-3406

josiedavison@metagenics.com

Jack Butler

ImpediMed

585-248-2554

jbutler@impedimed.com


'/>"/>
SOURCE ImpediMed Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
3. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
4. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
5. Synthetech Announces New Director of Manufacturing
6. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
7. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Helix BioPharma Announces $11.4 Million Private Placement
11. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):